Format

Send to

Choose Destination
Prostate. 2007 May 15;67(7):701-13.

IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats.

Author information

1
Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois, USA.

Abstract

BACKGROUND:

IRL-1620, a potent endothelin B receptor agonist, enhanced the efficacy of paclitaxel in a breast tumor model, but its effect in prostate cancer is not known. The present study was conducted to evaluate the effect of IRL-1620 on tumor perfusion, uptake of [(14)C]-doxorubicin in the tumor and efficacy of doxorubicin (DOX), and 5-flurouracil (5-FU) in a rat prostate tumor model.

METHODS:

JHU-4 (Mat-Lu) cells inoculated prostate tumor model in Copenhagen rats was used for the study.

RESULTS:

Administration of IRL-1620 (3 nmol/kg, i.v) significantly increased (102.8%) prostate tumor perfusion and tumor uptake of [(14)C]-doxorubicin (115%) compared to vehicle treated rats. Results of the efficacy study demonstrate that IRL-1620 administration 15 min prior to DOX (5 mg/kg) or 5-FU (50 mg/kg) on every third day for a total of four doses significantly reduced tumor volume compared to vehicle treated rats.

CONCLUSIONS:

IRL-1620 significantly enhanced the uptake and efficacy of anticancer agents in prostate cancer.

PMID:
17342753
DOI:
10.1002/pros.20556
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center